Genspect Exclusive: The Hidden Clause in Trump’s Executive Order — The Downfall of WPATH (Again)?

Stella O’Malley and Amanda Miller unpack Section 3(a)(ii)’s hidden power.

Photo by David Trinks on Unsplash

On January 28, 2025, President Trump signed an executive order provocatively titled "Protecting Children from Chemical and Surgical Mutilation." Since then, public discussion has focused almost exclusively on funding provisions and insurance coverage restrictions. But this narrow focus has caused nearly everyone to miss what may prove to be WPATH’s undoing: Section 3(a)(ii).

This overlooked clause came to Genspect’s attention during a meeting with HHS officials on Capitol Hill for #DetransAwarenessDay — and we are bringing it to public light for the first time here. Section 3(a)(ii) instructs the Secretary of Health and Human Services to “publish a review of the existing literature on best practices for promoting the health of children who assert gender dysphoria” within 90 days.

We have since confirmed through reliable sources that a Cass-like systematic review will be published by April 28, 2025. This review has the potential to reshape the landscape of gender-related healthcare for children in the United States.

The Review that should end WPATH

While funding restrictions may shift with each administration, this systematic review represents something far more enduring: a rigorous, government-led scientific assessment. It will expose the hollow core of WPATH’s recommendations – already criticized by many analysts of the gender-affirming care approach, but this time the critique will carry the authority of the HHS. Anyone who has been following the trans phenomenon will welcome this with a sense of relief, recognizing it as a long-overdue step towards greater clarity, accuracy, and a more balanced discussion.

The executive order does not mince words, describing WPATH’s guidance as “lacking scientific integrity” and instructing federal agencies to “rescind or amend all policies that rely on WPATH guidance.” This directive marks a turning point. WPATH has long refused to address Europe’s increasing restrictions on pediatric transition, showing a willful disregard for the evidence behind those changes. But with a federal review now emerging from within the U.S. health system itself, that strategy will be far harder to sustain.

We’ve seen this story unfold across Europe. Finland, Sweden, Denmark, Norway, the UK, Italy, and France have all restricted medical interventions for gender-dysphoric youth based on reviews of the same evidence WPATH uses in its guidelines. These assessments reached the same conclusion: medical transition on minors is a failed approach, supported by poor-quality evidence, substantial risks, and only theoretical, self-reported benefits.

But even with these reviews in hand, the culture of trans ideology has remained in these regions. In the UK, the NHS has managed to maintain a gender service that remains deeply ideological, and provides gender-affirming care that relies on a flawed informed consent model for highly vulnerable adults. We must ensure the same does not happen in the United States.

From Buried Evidence to Federal Action

So why hasn’t this review clause made headlines? Perhaps because systematic reviews lack the drama of funding fights, or because many underestimate its significance. But this one is different. It could apply federal standards to the evidence base, with implications for healthcare regulations, medical liability, and insurance coverage across the country.

The “WPATH Files” have already exposed deep contradictions: internal emails showing leaders privately acknowledging evidence gaps while publicly asserting scientific consensus. Even more damning were court documents from Alabama revealing that WPATH had commissioned systematic reviews from Johns Hopkins—which found insufficient evidence to support pediatric transition—and then suppressed the results.

The upcoming HHS review will complete what those buried reviews started. This time, however, federal authority ensures WPATH cannot bury the findings.

Beware the Post-Cass Complacency Trap

What happens after April 28? If the UK experience is anything to go by, there may be a wave of complacency from those who believe “the science has spoken.” But scientific clarity alone will not undo entrenched systems.

As Genspect is a global organization we are learning from other regions. If we look at Great Britain, we will see that there could be a sense of relief from those who believe that the science will pull us through. Perhaps there will be a rush to publish papers supporting the HHS review, as the scholars will not be so timid as they have been until now. But the UK showed that even after a landmark review, harmful practices can quietly continue—the US must not let clarity be mistaken for closure. In Genspect we have come to understand that it is imperative that we get to the nub of the issue:

- we have never medicalized identities before.

- medicalizing the identities of vulnerable children is a reckless intervention —at odds with the evidence, rooted in unproven theories, and blind to the underlying causes of distress.

- the evidence suggests that the vast majority of children who undergo medical transition will be harmed by these interventions.

To medicalize the identities of children is a reckless medical experiment that is causing devastation across the western world.

Crucially, the executive order also mandates that HHS “increase the quality of data” guiding treatment for minors. This is a long-overdue admission that the current model has been built on lies, sustained by misinformation, and justified through shoddy, poor-quality evidence masquerading as science. We need rigorous, independent research that asks the right questions—research that compares gender dysphoria to conditions like anorexia, OCD, and body dysmorphia; that explores the role of internalized homophobia in same-sex attracted youth; that examines the profound impact of autism and ADHD on gender identity development. We urgently need studies into how online communities, social contagion, and peer dynamics shape adolescent identity. These are the complex, uncomfortable areas WPATH has long minimized or ignored—yet they are precisely where clarity is most needed.

When the HHS review is published, it will catalyze a transformation in American healthcare. Practitioners adhering to WPATH’s guidance despite documented evidence gaps will face new liability risks. Medical associations that uncritically backed the affirmation-only model will face a deepening credibility crisis—driven by internal dissent, public backlash, legal challenges, and a growing recognition that they abandoned scientific rigor in favor of political conformity. Insurance companies will reconsider coverage, and pediatric transition clinics will become financially unsustainable, becoming known as extreme body modification centers rather than legitimate healthcare providers.

WPATH’s Last Stand

WPATH will likely contest the review, but their position appears untenable as the HHS assessment will mirror other rigorous global evaluations. In this instance, WPATH cannot rely on their standard responses. When faced with the WPATH Files evidence, their president Marci Bowers brilliantly defended their position by announcing "the world is not flat" – apparently mixing up medical research with a third-grade geography lesson. Such cosmic wisdom will inevitably crumble when confronted with a comprehensive federal review carrying the full weight of governmental authority.

We predict their strategy will pivot swiftly. They’ll shift from relying upon science to emphasizing human rights, calling for an “informed consent” model as the new standard. They’ve already made this shift but they will lean more heavily into it now. But we must be clear: the informed consent model is inappropriate for children and vulnerable adults and it is meaningless without honest disclosure about risks, outcomes, and the lack of long-term data. WPATH’s Standards of Care were never scientific documents—they only claimed to be, and far too many institutions believed them. The gender-affirming care brigade never had the science to back up their retrograde interventions.

The fallout will extend far beyond WPATH. Thousands of young people have already been harmed by medical transition, and WPATH has offered no roadmap for detransitioners or those suffering complications. Genspect is the only organization providing structured support to this growing population.

As WPATH’s influence diminishes, there is growing recognition of the need for a broader range of perspectives in this field. Genspect aims to contribute meaningfully to the evolving conversation. Our first book, The Gender Framework, will be published this year by Pitchstone Publishing. It outlines how a non-medicalized approach to gender dysphoria that prioritizes biological sex over gender can work across healthcare, education, and wider society.

Where WPATH prioritizes hormones and surgeries, our Beyond Trans program offers something different: comprehensive psychosocial care that balances compassion with evidence-based support to people who are experiencing gender dysphoria. We believe this is what genuine and effective care looks like, and the forthcoming HHS review is likely to agree.

April 28: The Reckoning Begins

With the release of the HHS review, a transformation in American healthcare could begin. Clinics will hopefully face growing pressure to abandon ideology in favor of psychosocial care—or face regulatory consequences. Medical education could be forced to confront the failures of affirmation-only practices. Someday soon, people will come to see that socially transitioning children in schools without parental permission is profoundly inappropriate, and the practice will no longer be tolerated.

We also look forward to puberty blockers being acknowledged as failed interventions—never appropriate for vulnerable youth.

April 28 represents more than a policy milestone; it marks a long-overdue course correction. For parents who resisted medicalization, clinicians who urged caution, and detransitioners left behind, the federal government will finally acknowledge what many have known all along: vulnerable individuals were subjected to experimental treatments without sound evidence, while the psychosocial care they needed was sidelined.

Mark it in your diary. This won't just be another day of press releases and policy briefings. It could be the moment the oil tanker finally begins to turn. In a right and just world, it will mark WPATH's reckoning—and the collapse of gender-affirming care as we know it.

For those already harmed, it comes too late. But for those who may now be protected, it offers a glimmer of hope—and the chance to finally choose a better path forward.